Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TS-142 residual effects in healthy elderly
NCT05819710Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- May 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vornorexant in Insomnia (4 arms), sponsored by Taisho Pharmaceutical. Primary endpoint: Root Mean Square of Center of Pressure in eye-open condition. Started May 2023; status: completed.
02
Drugs
vornorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT05819710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05819710.